Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Gamma Vacuum Foil (GVF) Versus Cross-linked Polyethylene in Total Knee Arthroplasty Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
DePuy Orthopaedics
ClinicalTrials.gov Identifier:
NCT00289133
First received: February 7, 2006
Last updated: May 31, 2016
Last verified: May 2016
Results First Received: May 30, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Osteoarthritis, Knee
Arthritis, Rheumatoid
Intervention: Device: total knee arthroplasty

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
GVF Poly Gamma Vacuum Foil polyethylene tibial component
XLK Poly Cross-linked polyethylene tibial component

Participant Flow:   Overall Study
    GVF Poly   XLK Poly
STARTED   461   477 
COMPLETED   189   179 
NOT COMPLETED   272   298 
Non-study device implanted                12                0 
Protocol Violation                32                38 
Withdrawal by Subject                9                10 
Death                5                10 
Lost to Follow-up - Hurricane Katri                73                74 
Physician Decision                41                45 
Revision                8                6 
Lost to Follow-up                92                115 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Enrolled Subjects

Reporting Groups
  Description
GVF Poly

Gamma Vacuum Foil polyethylene tibial insert

total knee arthroplasty: Gamma Vacuum Foil polyethylene tibial insert

XLK Poly

Cross-linked polyethylene tibial insert

total knee arthroplasty: cross-linked polyethylene tibial insert

Total Total of all reporting groups

Baseline Measures
   GVF Poly   XLK Poly   Total 
Overall Participants Analyzed 
[Units: Participants]
 449   477   926 
Age 
[Units: Years]
Mean (Standard Deviation)
 66.3  (8.5)   66.4  (8.5)   66.3  (8.5) 
Gender 
[Units: Participants]
     
Female   290   308   598 
Male   159   169   328 
Region of Enrollment 
[Units: Participants]
     
United States   449   477   926 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Survivorship (Revision of Any Component for Any Reason)   [ Time Frame: 5 years ]

2.  Secondary:   American Knee Society Evaluation - Total Score   [ Time Frame: 2 year ]

3.  Secondary:   American Knee Society Evaluation - Total Score   [ Time Frame: Minimum 5 years, up to 7.6 years ]

4.  Secondary:   Western Ontario and McMaster Universities Arthritis Index (WOMAC) Osteoarthritis Total Score   [ Time Frame: 2 year ]

5.  Secondary:   Western Ontario and McMaster Universities Arthritis Index (WOMAC) Osteoarthritis Total Score   [ Time Frame: Minimum 5 years, up to 7.6 years ]

6.  Secondary:   Radiographic Outcomes - Percentage of Knees With Femoral Radiolucencies (>2mm)   [ Time Frame: Minimum 5 years, up to 7.6 years ]

7.  Secondary:   Radiographic Outcomes - Percentage of Knees With Tibial Radiolucencies (>2mm)   [ Time Frame: Minimum 5 years, up to 7.6 years ]

8.  Secondary:   Radiographic Outcomes - Percentage of Knees With Femoral Osteolysis (>2mm)   [ Time Frame: Minimum 5 years, up to 7.6 years ]

9.  Secondary:   Radiographic Outcomes - Percentage of Knees With Tibial Osteolysis (>2mm)   [ Time Frame: Minimum 5 years, up to 7.6 years ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Serious adverse events were not collected in this study per the modern definition. All adverse events collected for this study will be reported in the 'Other Adverse Events' table. MedDRA was used to classify each AE into SOC, but not Preferred Term.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Clinical Portfolio Leader
Organization: DePuy Orthopaedics, Inc.
phone: 574-372-7231
e-mail: shimden@its.jnj.com



Responsible Party: DePuy Orthopaedics
ClinicalTrials.gov Identifier: NCT00289133     History of Changes
Other Study ID Numbers: 03111
Study First Received: February 7, 2006
Results First Received: May 30, 2014
Last Updated: May 31, 2016
Health Authority: United States: Institutional Review Board